Cargando…
A Device Improves Signs and Symptoms of TMD
BACKGROUND: Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. METHODS: 50 females with myofascial TMD accordi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526566/ https://www.ncbi.nlm.nih.gov/pubmed/31198477 http://dx.doi.org/10.1155/2019/5646143 |
_version_ | 1783419913783738368 |
---|---|
author | Monaco, Annalisa Pietropaoli, Davide IAPNOR, Cooper, Barry C. Ortu, Eleonora |
author_facet | Monaco, Annalisa Pietropaoli, Davide IAPNOR, Cooper, Barry C. Ortu, Eleonora |
author_sort | Monaco, Annalisa |
collection | PubMed |
description | BACKGROUND: Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. METHODS: 50 females with myofascial TMD according to RDC/TMD were randomly assigned to study (n = 25) and control groups (n = 25). At T0, both groups received sEMG/KNG and pain evaluation by the VAS scale. The study group received the ELIBA device (lingual elevator by Balercia) constructed under ULF-TENS (ultra-low-frequency transcoutaneous electrical nervous stimulation). Subjects were instructed to use ELIBA at least for 16 h/day. After 6 months (T1), both groups underwent to sEMG/KNG and VAS revaluation. RESULTS: T1 study group compared to controls showed a significant reduction in total (p < 0.0001) and mean (p < 0.0001) sEMG values, as well as a significant increase in both maximum vertical mouth opening (p=0.003) and maximum velocity in mouth opening (p=0.003) and closing (p < 0.0001). Interestingly, a significant reduction in pain measured by VAS (p < 0.0001) was reported. CONCLUSIONS: After 6 months, the ELIBA device is able to significantly reduce TMD-associated myogenous pain and to promote the enhancement of sEMG/KNG values. Practical Implications. ELIBA can be considered as a new device, potentially useful for head-neck pain relief in patients suffering from chronic TMD. In addition, its use promotes a muscles relaxation inducing freeway space increase. This characteristic makes it particularly useful for rehabilitation of patients with not enough space for construction of conventional orthotics or neuromuscular bites. |
format | Online Article Text |
id | pubmed-6526566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-65265662019-06-13 A Device Improves Signs and Symptoms of TMD Monaco, Annalisa Pietropaoli, Davide IAPNOR, Cooper, Barry C. Ortu, Eleonora Pain Res Manag Research Article BACKGROUND: Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. METHODS: 50 females with myofascial TMD according to RDC/TMD were randomly assigned to study (n = 25) and control groups (n = 25). At T0, both groups received sEMG/KNG and pain evaluation by the VAS scale. The study group received the ELIBA device (lingual elevator by Balercia) constructed under ULF-TENS (ultra-low-frequency transcoutaneous electrical nervous stimulation). Subjects were instructed to use ELIBA at least for 16 h/day. After 6 months (T1), both groups underwent to sEMG/KNG and VAS revaluation. RESULTS: T1 study group compared to controls showed a significant reduction in total (p < 0.0001) and mean (p < 0.0001) sEMG values, as well as a significant increase in both maximum vertical mouth opening (p=0.003) and maximum velocity in mouth opening (p=0.003) and closing (p < 0.0001). Interestingly, a significant reduction in pain measured by VAS (p < 0.0001) was reported. CONCLUSIONS: After 6 months, the ELIBA device is able to significantly reduce TMD-associated myogenous pain and to promote the enhancement of sEMG/KNG values. Practical Implications. ELIBA can be considered as a new device, potentially useful for head-neck pain relief in patients suffering from chronic TMD. In addition, its use promotes a muscles relaxation inducing freeway space increase. This characteristic makes it particularly useful for rehabilitation of patients with not enough space for construction of conventional orthotics or neuromuscular bites. Hindawi 2019-05-06 /pmc/articles/PMC6526566/ /pubmed/31198477 http://dx.doi.org/10.1155/2019/5646143 Text en Copyright © 2019 Annalisa Monaco et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Monaco, Annalisa Pietropaoli, Davide IAPNOR, Cooper, Barry C. Ortu, Eleonora A Device Improves Signs and Symptoms of TMD |
title | A Device Improves Signs and Symptoms of TMD |
title_full | A Device Improves Signs and Symptoms of TMD |
title_fullStr | A Device Improves Signs and Symptoms of TMD |
title_full_unstemmed | A Device Improves Signs and Symptoms of TMD |
title_short | A Device Improves Signs and Symptoms of TMD |
title_sort | device improves signs and symptoms of tmd |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526566/ https://www.ncbi.nlm.nih.gov/pubmed/31198477 http://dx.doi.org/10.1155/2019/5646143 |
work_keys_str_mv | AT monacoannalisa adeviceimprovessignsandsymptomsoftmd AT pietropaolidavide adeviceimprovessignsandsymptomsoftmd AT iapnor adeviceimprovessignsandsymptomsoftmd AT cooperbarryc adeviceimprovessignsandsymptomsoftmd AT ortueleonora adeviceimprovessignsandsymptomsoftmd AT monacoannalisa deviceimprovessignsandsymptomsoftmd AT pietropaolidavide deviceimprovessignsandsymptomsoftmd AT iapnor deviceimprovessignsandsymptomsoftmd AT cooperbarryc deviceimprovessignsandsymptomsoftmd AT ortueleonora deviceimprovessignsandsymptomsoftmd |